Clinical Trials Logo

Carcinoma, Ovarian Epithelial clinical trials

View clinical trials related to Carcinoma, Ovarian Epithelial.

Filter by:
  • Recruiting  
  • « Prev · Page 40

NCT ID: NCT02408536 Recruiting - Clinical trials for Recurrent Invasive Borderline Serous Ovarian Cancer

Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer

MITO 22
Start date: October 2014
Phase:
Study type: Observational

The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.

NCT ID: NCT02302742 Recruiting - Breast Cancer Clinical Trials

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

PROGECT
Start date: March 22, 2011
Phase:
Study type: Observational [Patient Registry]

PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).

NCT ID: NCT00703105 Recruiting - Ovarian Cancer Clinical Trials

Ovarian Dendritic Cell Vaccine Trial

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if a dendritic cell vaccine made with autologous tumor lysate or for patients who are HLA-A2 with peptides of MUC1 and WT1 therapy will produce remissions in patients with advanced ovarian cancer. This research is being done because we want to find new therapies for treatment of relapsed or refractory (resistant to ordinary treatment) ovarian cancer. The use of vaccine therapy is research. A new experimental approach for treating refractory or relapsed ovarian cancer involves using the patients own immune system to kill the cancer cells. These immune cells are called monocytes and are harvested from blood. The process of Leukapheresis collects the monocytes called Dendritic Cells. This is usually a 3 hour process done in the comfort of a hospital bed in the apheresis lab, similar to giving blood for donation. Approximately 300cc's are collected during this process, the equivalent of about 10 ounces of blood. Once these dendritic cells are collected - a special laboratory grows and processes them into a vaccine using a patient's own tumor cells or for those with a specific HLA type (HLA-A2) with tumor peptides. This preparation is then given back to the patient hopefully to stimulate the immune system to kill cancer cells. This type of treatment is considered biological research.

NCT ID: NCT00539162 Recruiting - Ovarian Cancer Clinical Trials

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Start date: July 2, 2001
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to evaluate a method involving a blood test, called CA-125, that may be helpful in the early detection of ovarian cancer in women who are at low risk.

NCT ID: NCT00488878 Recruiting - Clinical trials for Primary Peritoneal Carcinoma

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

Start date: May 19, 2006
Phase:
Study type: Observational

This study collects information to maintain a database on patients with low-grade ovarian or peritoneal tumors. Collecting information about the type of cancer and treatment, as well as details about follow-up care, may help researchers learn and better understand these tumor types and help develop better treatments for them.

NCT ID: NCT00005095 Recruiting - Ovarian Cancer Clinical Trials

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Start date: March 2000
Phase:
Study type: Observational

RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.